Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease

Cosnes, 2002, Long-term evolution of disease behavior of Crohn's disease, Inflamm Bowel Dis Jul, 8, 244, 10.1097/00054725-200207000-00002 Gumaste, 1992, Benign and malignant colorectal strictures in ulcerative colitis, Gut Jul, 33, 938, 10.1136/gut.33.7.938 Louis, 2003, Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype, Gut Apr, 52, 552, 10.1136/gut.52.4.552 Farmer, 1985, Long-term follow-up of patients with Crohn's disease, Relationship between the clinical pattern and prognosis. Gastroenterology Jun, 88, 1818 Fazio, 1993, Long-term follow-up of strictureplasty in Crohn's disease, Dis Colon Rectum Apr, 36, 355, 10.1007/BF02053938 Rieder, 2013, The gut microbiome in intestinal fibrosis:environmental protector or provocateur, Sci Transl Med Jun 19, 5, 190 Adler, 2011, The prognostic power of the NOD2 genotype for complicated Crohn's disease:a meta-analysis, Am J Gastroenterol Apr, 106, 699, 10.1038/ajg.2011.19 Meijer, 2007, Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease, World J Gastroenterol Jun 7, 13, 2960, 10.3748/wjg.v13.i21.2960 Henckaerts, 2009, Genetic risk profiling and prediction of disease course in Crohn's disease patients, Clin Gastroenterol Hepatol Sep, 7, 972, 10.1016/j.cgh.2009.05.001 Weersma, 2009, Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort, Am J Gastroenterol Mar, 104, 630, 10.1038/ajg.2008.112 Beaugerie, 2006, Predictors of Crohn's disease, Gastroenterology Mar, 130, 650, 10.1053/j.gastro.2005.12.019 Silverberg, 2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease:report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol Sep, 19, 5A, 10.1155/2005/269076 Dotan, 2006, Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease, Gastroenterology Aug, 131, 366, 10.1053/j.gastro.2006.04.030 Dubinsky, 2006, Serum immune responses predict rapid disease progression among children with Crohn's disease:immune responses predict disease progression, Am J Gastroenterol Feb, 101, 360, 10.1111/j.1572-0241.2006.00456.x Rieder, 2011, Predictors of fibrostenotic Crohn's disease, Inflamm Bowel Dis Sep, 17, 2000, 10.1002/ibd.21627 Kjeldsen, 1995, Seromarkers of collagen I and III metabolism in active Crohn's disease, Relation to disease activity and response to therapy. Gut Dec, 37, 805 Koutroubakis, 2003, Serum laminin and collagen IV in inflammatory bowel disease, J Clin Pathol Nov, 56, 817, 10.1136/jcp.56.11.817 Loeschke, 1989, Procollagen-III-peptide in the serum of patients with Crohn disease, Z Gastroenterol Mar, 27, 137 Allan, 1989, Plasma fibronectin in Crohn's disease, Gut May, 30, 627, 10.1136/gut.30.5.627 Di, 2004, Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease, Inflamm Bowel Dis Sep, 10, 573, 10.1097/00054725-200409000-00011 Rockey, 2009, Liver biopsy, Hepatology Mar, 49, 1017, 10.1002/hep.22742 Duarte-Rojo, 2012, Noninvasive markers of fibrosis:key concepts for improving accuracy in daily clinical practice, Ann Hepatol Jul, 11, 426, 10.1016/S1665-2681(19)31456-5 Parkes, 2011, Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C, J Viral Hepat Jan, 18, 23, 10.1111/j.1365-2893.2009.01263.x Rosenberg, 2004, Serum markers detect the presence of liver fibrosis:a cohort study, Gastroenterology Dec, 127, 1704, 10.1053/j.gastro.2004.08.052 Castera, 2012, Noninvasive methods to assess liver disease in patients with hepatitis B or C, Gastroenterology May, 142, 1293, 10.1053/j.gastro.2012.02.017 Ladero, 2012, Serum cystatin C:a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C, Ann Hepatol Sep, 11, 648, 10.1016/S1665-2681(19)31437-1 Castera, 2008, Non-invasive evaluation of liver fibrosis using transient elastography, J Hepatol May, 48, 835, 10.1016/j.jhep.2008.02.008 Tsochatzis, 2011, Elastography for the diagnosis of severity of fibrosis in chronic liver disease:a meta-analysis of diagnostic accuracy, J Hepatol Apr, 54, 650, 10.1016/j.jhep.2010.07.033 Huwart, 2008, Magnetic resonance elastography for the noninvasive staging of liver fibrosis, Gastroenterology Jul, 135, 32, 10.1053/j.gastro.2008.03.076 Yin, 2007, Assessment of hepatic fibrosis with magnetic resonance elastography, Clin Gastroenterol Hepatol Oct, 5, 1207, 10.1016/j.cgh.2007.06.012 Boursier, 2011, A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C, Am J Gastroenterol Jul, 106, 1255, 10.1038/ajg.2011.100 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, Am J Respir Crit Care Med Jan 15, 165, 277, 10.1164/ajrccm.165.2.ats01 Cicchitto, 2013, Idiopathic pulmonary fibrosis:the need for early diagnosis, Multidiscip Respir Med, 8, 53, 10.1186/2049-6958-8-53 Rosas, 2008, MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis, PLoS Med Apr 29, 5 Prasse, 2009, Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med Apr 15, 179, 717, 10.1164/rccm.200808-1201OC Furuhashi, 2010, Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis, Respir Med Aug, 104, 1204, 10.1016/j.rmed.2010.02.026 Korthagen, 2011, Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis, Respir Med Jan, 105, 106, 10.1016/j.rmed.2010.09.012 Kadota, 2005, High plasma concentrations of osteopontin in patients with interstitial pneumonia, Respir Med Jan, 99, 111, 10.1016/j.rmed.2004.04.018 Pardo, 2005, Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis, PLoS Med Sep, 2 Okamoto, 2011, Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias, Eur Respir J May, 37, 1119, 10.1183/09031936.00059810 Kono, 2011, Plasma CCN2 (connective tissue growth factor;CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF), Clin Chim Acta Nov 20, 412, 2211, 10.1016/j.cca.2011.08.008 Huang, 2013, Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan, Biosci Trends Aug, 7, 172 Zhang, 2012, Biomarkers in idiopathic pulmonary fibrosis, Curr Opin Pulm Med Sep, 18, 441, 10.1097/MCP.0b013e328356d03c Moeller, 2009, Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med Apr 1, 179, 588, 10.1164/rccm.200810-1534OC Gilani, 2010, CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of with idiopathic pulmonary fibrosis, PLoS One, 5, 10.1371/journal.pone.0008959 Kotsianidis, 2009, Global impairment of CD4 + CD25 + FOXP3 + regulatory T cells in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med Jun 15, 179, 1121, 10.1164/rccm.200812-1936OC Vij, 2012, Peripheral blood biomarkers in idiopathic pulmonary fibrosis, Transl Res Apr, 159, 218, 10.1016/j.trsl.2012.01.012 Dziadzio, 2005, N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma, QJM Jul, 98, 485, 10.1093/qjmed/hci078 Hesselstrand, 2008, COMP:a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker, Ann Rheum Dis Sep, 67, 1242, 10.1136/ard.2007.082099 Kim, 2005, Elevated matrix metalloproteinase-9 in patients with systemic sclerosis, Arthritis Res Ther, 7, R71, 10.1186/ar1454 Lorenzen, 2010, Osteopontin in the development of systemic sclerosis—relation to disease activity and organ manifestation, Rheumatology (Oxford) Oct, 49, 1989, 10.1093/rheumatology/keq223 Macko, 2002, Increased circulating concentrations of the counter-adhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma), Relationship to platelet and endothelial cell activation. J Rheumatol Dec, 29, 2565 Kikuchi, 1994, Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis, Arch Dermatol Res, 286, 77, 10.1007/BF00370731 Denton, 2007, Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis:a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192, Arthritis Rheum Jan, 56, 323, 10.1002/art.22289 Nagy, 2005, Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis, Clin Exp Rheumatol Mar, 23, 165 Kikuchi, 1995, Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis, J Am Acad Dermatol Dec, 33, 973, 10.1016/0190-9622(95)90289-9 Codullo, 2011, An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis, Ann Rheum Dis Jun, 70, 1115, 10.1136/ard.2010.137349 Giacomelli, 1997, Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease, Clin Exp Immunol Apr, 108, 42, 10.1046/j.1365-2249.1997.d01-991.x Sato, 2001, Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis, J Dermatol Sci Oct, 27, 140, 10.1016/S0923-1811(01)00128-1 Sato, 2004, Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis, Rheumatology (Oxford) Oct, 43, 1261, 10.1093/rheumatology/keh303 Kissin, 2006, Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis, Arthritis Rheum Nov, 54, 3655, 10.1002/art.22186 Lafyatis, 2009, B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis, Arthritis Rheum Feb, 60, 578, 10.1002/art.24249 Rodnan, 1979, Skin thickness and collagen content in progressive systemic sclerosis and localized sclero-derma, Arthritis Rheum Feb, 22, 130, 10.1002/art.1780220205 Madani, 2008, The role of radiology in the management of systemic sclerosis, Clin Radiol Sep, 63, 959, 10.1016/j.crad.2008.05.007 Moore, 2003, Seventeen-point dermal ultrasound scoring system—a reliable measure of skin thickness in patients with systemic sclerosis, Rheumatology (Oxford) Dec, 42, 1559, 10.1093/rheumatology/keg435 Lafyatis, 2012, Application of biomarkers to clinical trials in systemic sclerosis, Curr Rheumatol Rep Feb, 14, 47, 10.1007/s11926-011-0216-4 Moinzadeh, 2012, Biomarkers for skin involvement and fibrotic activity in scleroderma, J Eur Acad Dermatol Venereol Mar, 26, 267, 10.1111/j.1468-3083.2011.04206.x Cheng, 2006, Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis, Am J Transplant Oct, 6, 2292, 10.1111/j.1600-6143.2006.01493.x Gilbert, 2003, Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy, Diabetes Care Sep, 26, 2632, 10.2337/diacare.26.9.2632 Io, 2004, Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy, J Clin Lab Anal, 18, 14, 10.1002/jcla.10099 Tsakas, 2006, Accurate measurement and clinical significance of urinary transforming growth factor-beta1, Am J Nephrol, 26, 186, 10.1159/000093178 Torii, 2004, Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples, Rinsho Byori Jun, 52, 506 Sugiura, 2009, Resistive index predicts renal prognosis in chronic kidney disease, Nephrol Dial Transplant Sep, 24, 2780, 10.1093/ndt/gfp121 Zhu, 2013, Optimized pregelatinized starch technique for cell block preparation in cell cultures, Exp Mol Pathol Oct, 95, 144, 10.1016/j.yexmp.2013.06.009 Chen, 2012, miR-200b is involved in intestinal fibrosis of Crohn's disease, Int J Mol Med Apr, 29, 601, 10.3892/ijmm.2012.894 Zhang, 2013, Identification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics, Proteome Sci, 11, 30, 10.1186/1477-5956-11-30 Richards, 2012, Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med Jan 1, 185, 67, 10.1164/rccm.201101-0058OC Nie, 2013, Multiplexed salivary protein profiling for patients with respiratory diseases using fiber-optic bundles and fluorescent antibody-based microarrays, Anal Chem Oct 1, 85, 9272, 10.1021/ac4019523 Guerrot, 2012, Identification of periostin as a critical marker of progression/reversal of hypertensive ne-phropathy, PLoS One, 7, 10.1371/journal.pone.0031974 Geboes, 2000, Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis, Acta Gastroenterol Belg Oct, 63, 371 Graham, 1988, Collagen content and types in the intestinal strictures of Crohn's disease, Gastroenterology Feb, 94, 257, 10.1016/0016-5085(88)90411-8 Borley, 2001, Connective tissue changes in ileal Crohn's disease:relationship to disease phenotype and ulcer-associated cell lineage, Dis Colon Rectum Mar, 44, 388, 10.1007/BF02234738 Wegrowski, 1988, Modification of collagen and noncollagenous proteins in radiation-induced muscular fibrosis, Exp Mol Pathol Jun, 48, 273, 10.1016/0014-4800(88)90064-0 Geboes, 2001, Tenascin and strictures in inflammatory bowel disease:an immunohistochemical study, Int J Surg Pathol Oct, 9, 281, 10.1177/106689690100900404 Koukoulis, 2001, Obliterative muscularization of the small bowel submucosa in Crohn disease:a possible mechanism of small bowel obstruction, Arch Pathol Lab Med Oct, 125, 1331, 10.5858/2001-125-1331-OMOTSB Shelley-Fraser, 2012, The connective tissue changes of Crohn's disease, Histopathology Jun, 60, 1034, 10.1111/j.1365-2559.2011.03911.x Shepherd, 1987, Neuromuscular and vascular hamartoma of the small intestine:is it Crohn's disease, Gut Dec, 28, 1663, 10.1136/gut.28.12.1663 Breynaert, 2013, Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease, PLoS One, 8, 10.1371/journal.pone.0068876 Lawrance, 2001, Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease, Inflamm Bowel Dis Aug, 7, 226, 10.1097/00054725-200108000-00008 Maccioni, 2012, Value of T2-weighted magnetic resonance imaging in the assessment of wall inflammation and fibrosis in Crohn's disease, Abdom Imaging Dec, 37, 944, 10.1007/s00261-012-9853-y Punwani, 2009, Mural inflammation in Crohn disease:location-matched histologic validation of MR imaging features, Radiology Sep, 252, 712, 10.1148/radiol.2523082167 Fornasa, 2011, Role of magnetic resonance enterography in differentiating between fibrotic and active inflammatory small bowel stenosis in patients with Crohn's disease, J Clin Imaging Sci, 1, 35, 10.4103/2156-7514.82339 Adler, 2012, Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn's disease, Inflamm Bowel Dis May, 18, 849, 10.1002/ibd.21801 Larsson, 2006, Magnetic resonance imaging of experimental mouse colitis and association with inflammatory activity, Inflamm Bowel Dis Jun, 12, 478, 10.1097/00054725-200606000-00006 Mustafi, 2010, High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis, Magn Reson Med Apr, 63, 922, 10.1002/mrm.22229 Quarles, 2008, Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI, Magn Reson Med Sep, 60, 718, 10.1002/mrm.21724 Young, 2009, Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography, Neoplasia Mar, 11, 237, 10.1593/neo.81326 Ripolles, 2013, Effectiveness of contrast-enhanced ultrasound for characterisation of intestinal inflammation in Crohn's disease:a comparison with surgical histopathology analysis, J Crohns Colitis Mar, 7, 120, 10.1016/j.crohns.2012.03.002 Nylund, 2013, Quantitative contrast-enhanced ultrasound comparison between inflammatory and fibrotic lesions in patients with Crohn's disease, Ultrasound Med Biol Jul, 39, 1197, 10.1016/j.ultrasmedbio.2013.01.020 Kim, 2008, Non-invasive monitoring of tissue scaffold degradation using ultrasound elasticity imaging, Acta Biomater Jul, 4, 783, 10.1016/j.actbio.2008.02.010 Kim, 2008, Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease:animal model, Ultrasound Med Biol Jun, 34, 902, 10.1016/j.ultrasmedbio.2007.11.020 Stidham, 2011, Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease, Gastroenterology Sep, 141, 819, 10.1053/j.gastro.2011.07.027 van Swelm, 2013, Biomarkers for methotrexate-induced liver injury:urinary protein profiling of psoriasis patients, Toxicol Lett Aug 29, 221, 219, 10.1016/j.toxlet.2013.06.234 Hirasawa, 1997, KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts, Am J Respir Cell Mol Biol Oct, 17, 501, 10.1165/ajrcmb.17.4.2253 Ohnishi, 2002, Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases, Am J Respir Crit Care Med Feb 1, 165, 378, 10.1164/ajrccm.165.3.2107134 Greene, 2002, Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis, Eur Respir J Mar, 19, 439, 10.1183/09031936.02.00081102 Samukawa, 2012, The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D, BMC Pulm Med, 12, 55, 10.1186/1471-2466-12-55 Zhu, 2013, MicroRNAs:their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma, Exp Mol Med, 45, 10.1038/emm.2013.71 Hunzelmann, 1998, Circulating type I collagen degradation products:a new serum marker for clinical severity in patients with scleroderma, Br J Dermatol Dec, 139, 1020, 10.1046/j.1365-2133.1998.02558.x Yazawa, 2000, Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis, J Am Acad Dermatol Jan, 42, 70, 10.1016/S0190-9622(00)90011-2 Ishikawa, 2012, Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases, Respir Invest Mar, 50, 3, 10.1016/j.resinv.2012.02.001 Kinder, 2009, Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis, Chest Jun, 135, 1557, 10.1378/chest.08-2209 STX-100 in patients with idiopathic pulmonary fibrosis (IPF) Safety and efficacy of BIBF 1120 at high dose in idiopathic pulmonary fibrosis patients. Kawakami, 1998, Increased expression of TGF-beta receptors by scleroderma fibroblasts:evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype, J Invest Dermatol Jan, 110, 47, 10.1046/j.1523-1747.1998.00073.x Krieg, 1986, Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma, J Invest Dermatol Dec, 87, 788, 10.1111/1523-1747.ep12459865 Badra, 2010, Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients, Acta Microbiol Immunol Hung Mar, 57, 29, 10.1556/AMicr.57.2010.1.3 Berenguer, 2005, What determines the natural history of recurrent hepatitis C after liver transplantation, J Hepatol Apr, 42, 448, 10.1016/j.jhep.2005.01.011 Manzia, 2011, Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C, Transpl Int May, 24, 461, 10.1111/j.1432-2277.2011.01228.x Sanchez-Fueyo, 2002, Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft, Transplantation Jan 15, 73, 56, 10.1097/00007890-200201150-00010 Sethna, 2011, Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients:effect of rituximab, J Transplant, 2011, 389542, 10.1155/2011/389542